News | October 01, 2021
Merck to acquire Acceleron for US $ 11.5 billion
The acquisition complements and strengthens Merck’s cardiovascular pipeline
The acquisition complements and strengthens Merck’s cardiovascular pipeline
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)